WASHINGTON, D.C.—The workforce shortage in rheumatology is a looming crisis that demands immediate attention. The ACR’s 2015 Workforce Study projected that by 2030, the supply of adult rheumatologists would dwindle by 31%, in contrast to the increase in demand by close to 138%.1 The situation is even worse for pediatric rheumatology and in rural and…
WASHINGTON, D.C.—As of November 2024, there are 16 biologic disease-modifying anti-rheumatic drugs (bDMARDs) that are FDA approved for the treatment of psoriatic arthritis (PsA). Incredible news, right? But as my fellowship program director used to say, “There’s no free lunch.” This buffet of options is excellent for our patients, but poses challenges to the practicing…
Background/Purpose Psoriasis and psoriatic arthritis (PsA) are closely linked inflammatory conditions that can affect both children and adults. In children, these diseases are associated with traditional cardiovascular disease risk factors and subclinical atherosclerosis. In older adults, systemic inflammation from psoriasis and PsA accelerates atherosclerosis, and these conditions are independent risk factors for severe cardiovascular disease…
Burmester et al. characterized the long-term safety profile of upadacitinib treatment across multiple rheumatic diseases.
The most recent ACR/APLAR Research Exchange Program gave participants an opportunity to visit Singapore, learn from international research presentations and create connections with colleagues they may never otherwise have met.
The 2024 Rheumatology Research Workshop facilitated educational and relationship-building experiences for early-career and established rheumatology professionals alike.
With more than 350 research abstracts on systemic lupus erythematosus, lupus nephritis and related conditions accepted for presentation at ACR Convergence 2024, we’re happy to announce that Graciela S. Alarcón, MD, MPH, has accepted the monumental task of reviewing the abstracts and identifying those most likely to make a difference to clinical practice or lead…
Summaries of selected research abstracts on ANCA-associated vasculitis & IgA vasculitis from the International Vasculitis Workshop.
An ACR Convergence 2024 session will discuss strategies to educate patients about their disease and review the progress toward the concept of remission in gout to better guide physicians.
In a session at ACR Convergence 2024, expert panelists with go into depth concerning molecular mechanisms that contribute to gout pathogenesis.